At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 102 target
Drug / intervention
HLX42drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX42 (Anti-EGFR ADC) in Patients With Advanced/Metastatic Solid Tumors
In Brief
A Phase 1 clinical trial evaluating HLX42 for Solid Tumor and NSCLC. Currently recruiting, targeting 102 participants across 1 site.
Detailed Summary
This study is an open-label first-in-human phase I clinical study to evaluate the safety and tolerability of HLX42.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor and NSCLC
CountriesChina
Collaborators--
Timeline
Phase 1Recruiting
2024202520262027
First PostedJan 2024
Enrollment StartMar 2024
TodayJul 2026
Primary CompletionSep 2026
Study CompletionJun 2027
First PostedJan 18, 2024
Enrollment StartMar 14, 2024
Primary CompletionSep 2, 2026
Study CompletionJun 14, 2027
TodayJul 1, 2026
Enrollment to primary: 2.5 yearsPosted 2.5 years agoPrimary completion in 2 months
Interventions
HLX42drug
HLX42 is an anti-EGFR monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.